GlassScriptPhysician profile
Eileen P Carpenter
NPI 1053514711
$4,785.19
in general payments reported to CMS, 2019-2025
26 companies · $655 in 2025
The $655 reported for 2025 was more than what 90% of Obstetrics & Gynecology (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Obstetrics & Gynecology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,009 · 2022: $1,589 · 2023: $1,023 · 2024: $509 · 2025: $655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,026 · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,025.71 |
| Education | $161.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $873.55 | 2022 | |
| Abbvie INC. | $622.52 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $376.07 | 2021-2025 | |
| Exeltis, USA INC. | $339.93 | 2021-2025 | Slynd |
| Therapeuticsmd, INC. | $332.65 | 2021-2022 | |
| Aspira Women'S Health INC | $332.10 | 2021-2023 | Ova1 |
| Astellas Pharma US INC | $275.22 | 2023-2025 | Veozah |
| Millicent US INC | $210.31 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Pfizer INC. | $204.81 | 2021-2025 | |
| Coopersurgical, INC. | $162.68 | 2022-2025 | Paragard T 380a, Paragard T 380a |
| Myovant Sciences INC. | $146.37 | 2021-2022 | |
| Caldera Medical, INC | $124.36 | 2023 | Desara |
| Organon LLC | $114.25 | 2023 | Nexplanon |
| Hologic Sales and Service, LLC | $108.02 | 2023-2025 | Aptima, Novasure, Thinprep 2000 Processor |
| Avion Pharmaceuticals | $95.53 | 2021-2023 | Balcoltra |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $87.77 | 2023-2024 | Myfembree |
| Sage Therapeutics, LLC | $68.83 | 2024-2025 | Zurzuvae |
| Agile Therapeutics, INC. | $57.73 | 2021-2024 | Twirla |
| Renovia INC | $53.71 | 2021 | |
| Daiichi Sankyo INC. | $47.94 | 2021-2022 | |
| Mylan Pharmaceuticals INC. | $39.92 | 2021-2022 | |
| Shield Therapeutics INC | $35.76 | 2022-2024 | |
| Exact Sciences Corporation | $23.76 | 2023 | Cologuard Collection Kit |
| Evofem Biosciences, INC. | $19.79 | 2021 | |
| Sanofi Pasteur INC. | $17.24 | 2024 | |
| Amgen INC. | $14.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eileen Carpenter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.